Cargando…
Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study
Histamine H(3) receptor blockade may enhance lesion remyelination in multiple sclerosis (MS). The efficacy (using a magnetic resonance imaging marker of myelination, magnetisation transfer ratio [MTR]), safety and pharmacokinetics of GSK239512, a potent and brain penetrant H(3) receptor antagonist/i...
Autores principales: | Schwartzbach, Caryl J., Grove, Richard A., Brown, Robert, Tompson, Debra, Then Bergh, Florian, Arnold, Douglas L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306088/ https://www.ncbi.nlm.nih.gov/pubmed/27888416 http://dx.doi.org/10.1007/s00415-016-8341-7 |
Ejemplares similares
-
Probiotic supplementation and systemic inflammation in relapsing-remitting multiple sclerosis: A randomized, double-blind, placebo-controlled trial
por: Rahimlou, Mehran, et al.
Publicado: (2022) -
Quantitative Determination of Regional Lesion Volume and Distribution in Children and Adults with Relapsing-Remitting Multiple Sclerosis
por: Ghassemi, Rezwan, et al.
Publicado: (2014) -
Corrigendum: Probiotic supplementation and systemic inflammation in relapsing-remitting multiple sclerosis: A randomized, double-blind, placebo-controlled trial
por: Rahimlou, Mehran, et al.
Publicado: (2022) -
Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis: A Randomized, Placebo-Controlled Trial
por: Bellmann-Strobl, Judith, et al.
Publicado: (2021) -
Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations
por: Then Bergh, Florian, et al.
Publicado: (2006)